Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Innovation Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Innovation Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Innovation Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Innovation Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Innovation Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 10
Innovation Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Innovation Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Cellceutix Enters Into Agreement With University of Texas MD Anderson Cancer Center For Kevetrin Drug 12
Licensing Agreements 14
Cellceutix Enters Into Licensing Agreement For Cancer Compound 14
Equity Offering 15
Innovation Pharma to Raise USD30 Million in Private Placement of Shares 15
Cellceutix Raises USD16 Million in Private Placement of Common Stock 16
Cellceutix Raises USD2.2 Million in Private Placement of Shares 17
Cellceutix Announces Private Placement Of Common Stock For US$20 Million 18
Cellceutix Completes First Tranche Of Private Placement Of Common Stock For USD0.1 Million 19
Cellceutix Completes Private Placement Of Series a Convertible Preference Stock For US$1 Million 21
Acquisition 22
Cellceutix Completes Acquisition Of PolyMedix 22
Innovation Pharmaceuticals Inc – Key Competitors 23
Innovation Pharmaceuticals Inc – Key Employees 24
Innovation Pharmaceuticals Inc – Locations And Subsidiaries 25
Head Office 25
Recent Developments 26
Financial Announcements 26
Feb 16, 2017: Cellceutix Reports on Q2 Fiscal 2017, Prepares for Important Clinical Milestones 26
Nov 14, 2016: Cellceutix Provides Corporate Update and Reports Q1 Fiscal 2017 Financial Results 28
Corporate Communications 32
Aug 30, 2016: Cellceutix Further Expands Its Senior Managment Team With the Addition of an Industry Veteran 32
Jun 30, 2016: Cellceutix Announces Industry Veteran Arthur P. Bertolino, MD, PhD, MBA Joins Company as President and Chief Medical Officer 33
Mar 08, 2016: Cellceutix Welcomes Dr. Stephen T. Sonis to Its Scientific Advisory Board 34
Product Approvals 35
Feb 26, 2016: Cellceutix Submits Special Protocol Assessment Request to FDA for Phase III Clinical Trial of Brilacidin for ABSSSI 35
Jan 22, 2016: Cellceutix Releases Data Used in Receiving FDA Orphan Drug Designation of Kevetrin for Pancreatic Cancer 36
Jan 21, 2016: Cellceutix Receives FDA Orphan Drug Designation for Kevetrin for the Treatment of Pancreatic Cancer 37
Jan 19, 2016: Cellceutix Submits Briefing Book for Phase 2 Trial of p53 Targeting Drug for Ovarian Cancer 38
Clinical Trials 39
Apr 03, 2017: Cellceutix AACR Poster Presents Data Supporting Kevetrin Modulation of p53 in Multiple Human Ovarian Cancer Cell-lines and Corresponding Xenograft Tumors 39
Mar 03, 2017: Cellceutix Provides Update on Developing p53 Drug Candidate Kevetrin as an Oral Anti-Cancer Agent 40
Feb 22, 2017: Cellceutix Phase 2 Brilacidin Trial Progresses to Highest Dose Cohort for the Induction of Remission of Mild-to-Moderate Ulcerative Colitis 41
Feb 10, 2017: Cellceutix Announces Initiation of Main Clinical Site for Phase 2a Trial of p53 Drug Candidate Kevetrin in the Treatment of Platinum-Resistant/Refractory Ovarian Cancer 42
Jan 23, 2017: Cellceutix’s Brilacidin Demonstrates Promise in Treating Ulcerative Colitis Supported by Endoscopic Assessment, Patient-Reported Outcomes 43
Jan 17, 2017: Cellceutix Completes Enrollment in Second of Three Planned Cohorts in Phase 2 Clinical Trial of Brilacidin for Inflammatory Bowel Disease 44
Dec 19, 2016: Cellceutix Reports 24 Core Phase 2b Clinical Trial Sites for Oral Prurisol Treatment of Moderate-To-Severe Psoriasis Initiated and Open for Screening 45
Dec 07, 2016: Cellceutix Phase 2 Trial Dose Escalates in 2nd Cohort for Brilacidin as a Novel Anti-Inflammatory Drug Candidate for Ulcerative Colitis 46
Oct 31, 2016: Cellceutix Begins Phase 2b Clinical Trial of Oral Prurisol in Moderate-to-Severe Chronic Plaque Psoriasis 47
Oct 26, 2016: Cellceutix Novel Anti-Inflammatory Phase 2 Drug Candidate Brilacidin Builds Momentum Across Multiple Clinical Indications 48
Oct 10, 2016: Cellceutix Phase 2 Trial Initial Data Shows Potential of Brilacidin as a Novel Anti-Inflammatory Drug Candidate for the Induction of Remission of Mild-to-Moderate Ulcerative Colitis 50
Aug 03, 2016: Cellceutix Prepares Phase 2a Ovarian Cancer Trial of Kevetrin, a Novel p53-Modulating Drug Candidate, Based Upon Phase 1 Topline Data 51
Jul 21, 2016: Cellceutix Expedites Phase 2 Trial of Brilacidin-OM For Oral Mucositis 52
Jul 18, 2016: Cellceutix Receives Update on First Patient Enrolled in Phase 2 Proof-of-Concept Study of Brilacidin for Ulcerative Proctitis 53
Jul 07, 2016: Cellceutix to Initiate Phase 2b Trial of Prurisol for Chronic Plaque Psoriasis 54
Jun 15, 2016: Cellceutix Starts Phase 2 Trial of Brilacidin as a Novel Therapy for Ulcerative Proctitis 55
Jun 06, 2016: Cellceutix Announces Database Lock in Phase 1 Trial of Kevetrin, a Promising New Cancer Treatment That Activates p53 56
May 31, 2016: Cellceutix Releases Pharmacokinetics Data From Phase 2 Trial of Prurisol for Treating Psoriasis; Data Complements Efficacy Data Reported Last Week 57
May 26, 2016: Cellceutix Provides Additional Insight Into Successful Phase 2 Trial for Treating Psoriasis 58
May 24, 2016: Cellceutix Phase 2 Trial of Prurisol for Mild to Moderate Psoriasis Meets Primary Endpoint 59
May 11, 2016: Data From Phase 2 Trial of Prurisol for Psoriasis to Be Unblinded Next Week, Top-Line Results to Follow 61
Apr 19, 2016: Cellceutix Institutes “Database Soft Lock” on Its Phase 2 Psoriasis Clinical Trial, Top Line Results Anticipated in May; Additional Company Updates 62
Mar 31, 2016: Cellceutix Successfully Completes In Vitro Study in Support of Planned Phase 2 Trial of Kevetrin for Ovarian Cancer 64
Mar 30, 2016: Cellceutix Receives Preliminary Approval for Clinical Trial of Brilacidin for Ulcerative Proctitis 65
Mar 17, 2016: Cellceutix Concludes Last Patient Visit in Phase 2 FDA Trial of Oral Dosed Prurisol in Patients With Mild-to-Moderate Chronic Plaque Psoriasis 66
Mar 01, 2016: Cellceutix Completes Dosing in Phase 2 Trial of Prurisol for Chronic Psoriasis, Top-Line Data Anticipated in May 67
Feb 22, 2016: Assay Results From Cellceutix Phase 1 Clinical Trial of Kevetrin for Cancer Show Increased p21 Expression in 67.5% of Evaluable Patients 68
Feb 16, 2016: Cellceutix Completes Clinical Trial of Kevetrin for Advanced Solid Tumors 69
Feb 10, 2016: Cellceutix Meets With FDA for Phase 2 Clinical Trial of Kevetrin for Ovarian Cancer 70
Feb 09, 2016: Cellceutix to Submit Special Protocol Assessment Request to FDA for Phase 3 Clinical Study of Antibiotic Brilacidin for ABSSSI 71
Jan 25, 2016: Cellceutix Phase 2 Trial of New Oral Treatment for Psoriasis Nearing Completion 72
Jan 14, 2016: Brilacidin Lyophilized as Cellceutix Prepares to Bring First New Class of Antibiotic to Phase 3 Trials in More Than 20 Years 73
Other Significant Developments 74
Jun 07, 2017: Cellceutix Announces Company Name Change to Innovation Pharmaceuticals 74
May 10, 2017: Cellceutix Provides Corporate Update; Significant Milestones Ahead as Multiple Mid-Phase Clinical Trials Set to Conclude 75
Sep 13, 2016: Cellceutix Provides Business Update and Timeline of Upcoming Milestones 77
Appendix 78
Methodology 78
About GlobalData 78
Contact Us 78
Disclaimer 78
Innovation Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Innovation Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Innovation Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Innovation Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Innovation Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Innovation Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 10
Innovation Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Cellceutix Enters Into Agreement With University of Texas MD Anderson Cancer Center For Kevetrin Drug 12
Cellceutix Enters Into Licensing Agreement For Cancer Compound 14
Innovation Pharma to Raise USD30 Million in Private Placement of Shares 15
Cellceutix Raises USD16 Million in Private Placement of Common Stock 16
Cellceutix Raises USD2.2 Million in Private Placement of Shares 17
Cellceutix Announces Private Placement Of Common Stock For US$20 Million 18
Cellceutix Completes First Tranche Of Private Placement Of Common Stock For USD0.1 Million 19
Cellceutix Completes Private Placement Of Series a Convertible Preference Stock For US$1 Million 21
Cellceutix Completes Acquisition Of PolyMedix 22
Innovation Pharmaceuticals Inc, Key Competitors 23
Innovation Pharmaceuticals Inc, Key Employees 24
